Back to Search
Start Over
Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial
- Source :
- Journal of the American College of Cardiology. (6):505-512
- Publisher :
- American College of Cardiology Foundation. Published by Elsevier Inc.
-
Abstract
- ObjectivesWe sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD).BackgroundChronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system.MethodsAfter an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure
Details
- Language :
- English
- ISSN :
- 07351097
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.core.ac.uk....e4298e51b56d5f000b87f77c6d789227
- Full Text :
- https://doi.org/10.1016/j.jacc.2009.03.066